Stock IMNN IMUNON, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Imunon, Inc.

Equities

IMNN

US15117N6022

Market Closed - Nasdaq
Other stock markets
 21:30:01 29/04/2024 BST 		5-day change 1st Jan Change
1.355 USD -5.92% Intraday chart for Imunon, Inc. +6.68% +99.24%
04-18 Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine MT
04-18 Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine DJ

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101
Top Midday Gainers
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Imunon, Inc. Files Ind Application to Begin Human Testing of Imnn-101
IMUNON Names Executive Chairman as Temporary Head Following Resignation of CEO Corinne Le Goff
Imunon, Inc. Announces Executive Changes
Imunon, Inc. Announces Resignation of Corinne Le Goff as Chief Executive Officer, Effective March 15, 2024
Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer
Imunon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer
IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board
Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board
Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv
Imunon Opening New Manufacturing Facility in Alabama to Support Production of Vaccine Formulation Components
IMUNON, Inc. Unveils New Manufacturing Capabilities at Huntsville's HudsonAlpha Biotech Campus
Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors
Imunon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMNN Stock
  4. News Imunon, Inc.
  5. Other languages